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ABSTRACT Over 90% of the world’s population is persistently infected with
Epstein-Barr virus. While EBV does not cause disease in most individuals, it is the
common cause of acute infectious mononucleosis (AIM) and has been associated
with several cancers and autoimmune diseases, highlighting a need for a preventive
vaccine. At present, very few primary, circulating EBV genomes have been se-
quenced directly from infected individuals. While low levels of diversity and low viral
evolution rates have been predicted for double-stranded DNA (dsDNA) viruses, re-
cent studies have demonstrated appreciable diversity in common dsDNA pathogens
(e.g., cytomegalovirus). Here, we report 40 full-length EBV genome sequences ob-
tained from matched oral wash and B cell fractions from a cohort of 10 AIM pa-
tients. Both intra- and interpatient diversity were observed across the length of the
entire viral genome. Diversity was most pronounced in viral genes required for es-
tablishing latent infection and persistence, with appreciable levels of diversity also
detected in structural genes, including envelope glycoproteins. Interestingly, intrapa-
tient diversity declined signiﬁcantly over time (P  0.01), and this was particularly
evident on comparison of viral genomes sequenced from B cell fractions in early pri-
mary infection and convalescence (P  0.001). B cell-associated viral genomes were
observed to converge, becoming nearly identical to the B95.8 reference genome
over time (Spearman rank-order correlation test; r  0.5589, P  0.0264). The re-
duction in diversity was most marked in the EBV latency genes. In summary, our
data suggest independent convergence of diverse viral genome sequences toward a
reference-like strain within a relatively short period following primary EBV infection.
IMPORTANCE Identiﬁcation of viral proteins with low variability and high immuno-
genicity is important for the development of a protective vaccine. Knowledge of ge-
nome diversity within circulating viral populations is a key step in this process, as is
the expansion of intrahost genomic variation during infection. We report full-length
EBV genomes sequenced from the blood and oral wash of 10 individuals early in
primary infection and during convalescence. Our data demonstrate considerable di-
versity within the pool of circulating EBV strains, as well as within individual pa-
tients. Overall viral diversity decreased from early to persistent infection, particularly
in latently infected B cells, which serve as the viral reservoir. Reduction in B cell-
associated viral genome diversity coincided with a convergence toward a reference-
like EBV genotype. Greater convergence positively correlated with time after infec-
tion, suggesting that the reference-like genome is the result of selection.
KEYWORDS EBV, DNA sequencing, viral diversity, phylogenetic analysis, genome
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With a worldwide infection rate greater than 90%, Epstein-Barr Virus (EBV) ranks asone of the most successful human pathogens. The majority of primary EBV
infections occur early in life and are asymptomatic; primary infection in older children
or young adults frequently results in acute infectious mononucleosis (AIM) (1, 2). EBV
establishes a persistent infection in human hosts, characterized by nearly continuous
lytic infection in the oropharynx and latent infection of memory B cells (3). While EBV
does not cause disease in the majority of persistently infected individuals, it has been
associated with several cancers (Hodgkin’s and Burkitt’s lymphomas and nasopharyn-
geal and gastric carcinomas), as well as autoimmune diseases (systemic lupus erythem-
atosus and multiple sclerosis) (4–6). Although a vaccine is clearly needed, efforts to date
have failed to provide the level of sterilizing protection required to prevent EBV
infection and persistence (7–12).
Effective vaccine development beneﬁts from a detailed understanding of circulating
primary viral genome sequences and proteins. It has been generally assumed that
double-stranded DNA (dsDNA) viral genomes such as EBV are relatively stable due to
the proofreading capacity of eukaryotic DNA polymerases which restrict mutation rates
to approximately 109 substitutions/site/year (13). However, several recent reports
from our lab and others have demonstrated that even dsDNA viral genes and genomes
(e.g., cytomegalovirus [CMV] and EBV) display a measurable amount of variability within
an infected host at any time after infection (14–16). The origin of this variability is
unknown; it could be present in the initial viral inoculum, arise early during initial
rounds of infection and replication in epithelial cells or seeding of the B cell compart-
ment, or evolve as a result of immune escape over the course of chronic infection. In
addition, different levels of variation were detected among EBV genes within similar
cohorts (15, 16). Sequencing full-length genomes directly from patient samples over
the course of primary through persistent EBV infection is necessary to resolve these
questions.
Following primary infection, EBV establishes lifelong persistence characterized by a
latent reservoir of memory B cells and nearly continuous lytic replication in the
nasopharynx and tonsils. To date, direct ampliﬁcation and sequencing of EBV genomes
from peripheral blood cells (BC) and saliva or oral wash (OW) samples has been
hampered by the small proportion of viral genomes present compared to those of
human and other genomic DNA. The recent development of strategies to selectively
enrich EBV genomes from human samples and to remove contaminating human
genome reads have facilitated EBV sequencing directly from patient samples (17, 18).
Recently, several groups have demonstrated considerable global genomic diversity
over the full-length sequences of greater than 100 EBV genomes (17–25). However, the
bulk of these studies were conducted using diseased tissue or transformed primary cells
(18, 19, 23–26). Either of these two conditions (disease or tissue culture passage) may
have imposed selective pressures on the viral genomes, raising the question of how
representative they are of circulating and transmitted viral genomes (27, 28).
In this study, we have used methods to enrich and amplify EBV genomes from
peripheral blood B cell and oral wash samples obtained from 10 young adults present-
ing with acute infectious mononucleosis (AIM) and in convalescence (5 to 11 months
post-primary infection [CONV]). Genetic variability was detected in primary infection
across the length of the EBV genome and was most pronounced in latency genes,
consistent with previous reports. Most importantly, we observed a signiﬁcant reduction
in diversity in circulating B cell-derived viral sequences in convalescence, with conver-
gence toward a reference-like EBV genome (B95.8). To our knowledge, this is the largest
body of EBV sequencing data obtained directly ex vivo that clearly demonstrates early
genomic diversity and convergence of EBV genome sequences over the course of
primary EBV infection.
RESULTS
Enrichment of EBV genomes facilitates sequencing directly from patient sam-
ples. As noted in previous reports, the small proportion of viral genomes present in
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even puriﬁed B cell fractions presents a challenge for generating complete full-length
EBV next-generation sequencing libraries from infected patient samples (29). In the
absence of any puriﬁcation or enrichment strategy, the majority of the sequencing
reads align to the human genome. The recent development of biochemical strategies
to remove contaminating human genome reads has facilitated EBV sequencing directly
from patient samples (17, 18, 26).
Using an approach similar to one successfully employed to generate overlapping
RNA probes against the larger and more complex genome of Plasmodium falciparum
(30), EBV genomes were enriched from patient B cell or oral wash samples using
biotinylated RNA probes based on templates from type I reference EBV strains, B95.8
and Akata. Probe-genome hybrids were immobilized on NeutrAvidin-coated magnetic
beads, and stringent washes were employed to remove nonhybridized, contaminating
sequences. This markedly reduced the human genomic material in each sample, thus
increasing EBV-speciﬁc reads in each library, with commensurate increases in both
depth and breadth of coverage (31).
As proof of principle, the above enrichment protocol was used to capture and
resequence the EBV Akata bacterial artiﬁcial chromosome (BAC) mixed with 1.0  105
copies of human genome isolated from EBV-negative cultured cells. Following success-
ful genome enrichment and sequencing, paired reads with 99 to 100% presumed base
call accuracy, as indicated by FastQC statistics, were mapped to the B95.8 reference
genome (NCBI accession number NC_007605.1) for alignment and genome assembly.
The B95.8 reference genome was selected as a scaffold for our data set based on recent
reports suggesting that it is a representative type I EBV genome (18). Additionally,
several genomes were assembled by scaffolding to the Mutu reference genome (NCBI
accession number KC207814), and the full-length sequences were compared to those
scaffolded against B95.8; no important differences were noted, and, using a phyloge-
netic approach, it was shown that these genomes consistently branched identically to
their paired B95.8 assemblies. The resequenced EBV genome aligned to the Akata
reference genome deposited in NCBI (KC207813.1) to 96.7% identity, with the loss of
alignment coinciding with previously described areas of low sequencing depth and
high sequence repetition (18).
Utilizing these techniques, 40 EBV genomes were successfully enriched and se-
quenced from all 10 patients (two time points and two tissue types per patient) at an
average depth of 5,420 across the full-length genome. A consensus sequence for
each of the 40 sequenced samples was compiled and designated by patient code,
location of sample collection (BC or OW), and sample collection time (AIM or CONV).
Alignment of all 40 patient sequences to the B95.8 reference genome indicated
completeness of coverage (Fig. 1). Many single nucleotide polymorphisms (SNPs) and
identical bases were located throughout the alignment, as demonstrated by the height
and color (green to light green) in the identity plot. Several regions in the alignment,
denoted by blue boxes, were representative of EBV repeat regions, which typically
cannot be assembled when Illumina sequencing is used; previously reported sequenc-
ing information obtained by either Sanger sequencing or sequencing of high-copy-
number viral genomes isolated from transformed cell lines was used (32). These regions
were masked for all subsequent analysis. Comparison of fragment per kilobase million
(FPKM) values, taken as a measure of coverage per EBV open reading frame (ORF),
demonstrated comparable levels of sequencing depth, regardless of tissue of origin or
time of collection (see Table S2 in the supplemental material). Also highlighted is a
region containing the LF3 ORF; this ORF, located between bases 142000 and 145000 of
the reference genome, was not present in the original sequencing of B95.8 and has
been added to the reference using EBV sequences from Raji cells (33, 34). The function
of this region has yet to be determined, with some studies suggesting a coding
function and others suggesting a noncoding function (25, 35). In addition, although this
region is present in EBV associated with tumors, it is conspicuously absent in the only
other published full-length, primary EBV genome taken directly from saliva of an
otherwise healthy individual, as well as in our samples (18).
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Primary EBV genomes derived from cohort donors were exclusively type I. EBV
is segregated into two subtypes based largely on the sequences of four EBV genes,
speciﬁcally, EBNA2, EBNA3A, EBNA3B, and EBNA3C (36). The type I strain, predominantly
found in the Western Hemisphere as well parts of Southeast Asia, is represented by
reference genomes B95.8, Akata, Mutu, C666-1, M81, GD1, and GD2 (19, 24, 25, 32, 37,
38). Type II, which is codominant with type I and until recently was believed to be
restricted in distribution largely to sub-Saharan Africa, is represented by the reference
FIG 1 Overview of the features of the EBV genome and sequence diversity: alignment of 40 full-length genome sequences. The identity
plot derived from this alignment is shown at the top and is colored as follows: dark green, 100% identity; light green, 30 to 100%
identity; red, 30% identity. The black bar below represents a consensus sequence drawn from the alignment of the genomes of 40
EBV strains. Below the identity plot, EBV coding regions are shown in dark red, with arrows indicating the direction of the reading
frame. The blue boxes indicate regions of the multigenome alignment that failed to align properly. The bold red box indicates the
duplication in the LF3 ORF of the B95.8 reference genome that is missing in our patient cohort. These boxed regions were masked for
phylogenetic and genetic distance calculations.
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genomes of AG876, Jijoye, and Wewak (18, 39, 40). A midpoint-rooted maximum-
likelihood phylogenetic tree that includes these type I and II reference genomes
demonstrated that all EBV genomes sequenced from our patient cohort segregated
with type I strains (Fig. 2). None of the patient sequences branched with type II
reference genomes, indicating that our cohort was infected exclusively with type I EBV.
FIG 2 Forty full-length EBV viral genomes sequenced from 10 patients align almost exclusively with type I reference strains. EBV sequences
are labeled by source (peripheral blood B cells, BC; oral wash, OW) and timing of sample (AIM, within 2 weeks of diagnosis of acute
infectious mononucleosis; CONV, at least 6 months postinfection [highlighted with black dots]) during primary EBV infection. A
maximum-likelihood, midpoint-rooted phylogeny is shown, with each patient represented independently by color. EBV type II sequences
are boxed. All other sequences are derived from EBV type I. Sequences from the cohort are most closely related to B95.8 and Mutu isolates
(circled) and least related to Asian EBV type I isolates (GD1, Akata, GD2, M81, C666-1, and saliva sample from a healthy Asian donor), shown
at the top of the tree.
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In addition to subtypes, strong geographic segregation has been observed for type
I EBV strains (41). The Western reference strain, B95.8, was isolated from marmoset B
cells transformed by EBV from an elderly patient diagnosed with AIM following multiple
blood transfusions, while an African type I reference, Mutu, was taken from the tissue
of a Kenyan Burkitt lymphoma patient (25, 42). Several sequences of Asian origin have
been described: Akata, which was derived from a Japanese Burkitt lymphoma patient;
GD-1, GD-2, C666-1, and M81, which were sequenced from nasopharyngeal carcinoma
tissue and cell lines originating from Chinese patients (19, 24, 25, 37, 38). Also, a recently
reported full-length primary EBV sequence isolated from saliva of a healthy individual
believed by the authors to be of Asian descent clustered with this group (Fig. 2, healthy
donor saliva) (18). All patient sequences clustered closer to the prototypical type I
reference, B95.8, or to Mutu (blue ovals), the type I sequence presumed to originate
from Kenya, with the E1578 AIM sequences displaying the most diversity, as is evident
by the long branch lengths in comparison to those of other subject viruses.
EBV genomes sequenced from AIM patients display nucleotide variation across
the full genome. A recent report by Palser et al. provided sequence information for 83
different global EBV genomes and showed the highest levels of genetic variation,
including an increase in nonsynonymous substitutions, in open reading frames (ORFs)
associated with latent EBV genes (18). Only one primary saliva specimen was analyzed;
the remainder of EBV sequences were derived primarily from lymphoblastoid cell lines
(LCL) or tumors.
Access to a cohort of young adults experiencing primary EBV infection provided the
opportunity to sequence circulating EBV genomes directly from peripheral blood B cells
and oral wash samples over the course of primary infection and transition to persis-
tence. High levels of variation were detected in latent EBV genes, including EBNA1
(BKRF1), EBNA2, EBNA3A, EBNA3B, EBNA3C, LMP1, and LMP2, in agreement with previ-
ously published reports (Fig. 3A) (18). Synonymous and nonsynonymous substitutions
were evaluated across the EBV genome ORFs for all 40 sequences. For the analyses, we
segregated the EBV genome into latent, early lytic (early), and late lytic (late) genes and
compared the mean levels of synonymous and nonsynonymous nucleotide changes
within these gene groups (Fig. 3B). Nonsynonymous variation was signiﬁcantly higher
in the latency genes than in either early or late lytic genes (Mann-Whitney test;
nonsynonymous latent versus nonsynonymous early lytic, P  0.0004; nonsynonymous
latent versus late lytic, P  0.0002). At the gene level, only BCRF2 (tegument), EBNA-LP
(transcription cofactor), EBNA1/BKRF1 (DNA-binding, genome replication), and BNLF2a
(interleukin-10 [IL-10] homologue) demonstrated higher ratios of nonsynonymous/
synonymous (dN/dS) changes. All remaining EBV ORFs displayed higher levels of
synonymous than nonsynonymous variation, suggesting increased conservation at the
protein level, a ﬁnding that was supported by dN/dS analysis (Fig. 3C). Latent genes had
a statistically higher dN/dS ratio as a group than early or late genes (Mann-Whitney test;
latent versus early, P  0.0011; latent versus late, P  0.002); the mean ratio was 0.69,
suggesting some positive selection pressure, most likely due to the increased number
of nonsynonymous changes in EBNA-LP and EBNA1.
Intrahost and intracompartment EBV whole-genome diversity varies among
patients and sample time points. Having detected variation across the EBV genome
in our patient cohort, we next investigated intrahost genetic diversity for each patient
sequence population (Fig. 4A). Substantial differences in variation were identiﬁed
across our patient pool. One patient (E1503) displayed very little intrahost variation
across compartments (blood and oral wash) or time. In contrast, consensus sequences
from six patients (E1563, E1577, E1578, E1583, E1587, and E1590) showed higher
intrapatient variability. Next, pairwise genetic distances were calculated for consensus
sequences grouped by time point and compartment (BC AIM, OW AIM, BC CONV, and
OW CONV) (Fig. 4B). Mean levels of genetic variation were similar in viral sequences
from the B cell fraction and oral wash samples during AIM. However, the overall genetic
variation was signiﬁcantly reduced (P  0.01) in both compartments during CONV. We
then calculated the Tamura-Nei (TN93) genetic distance (see Materials and Methods)
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between each consensus sequence and the B98.5 reference genome (Fig. 4C). Again we
observed signiﬁcant differences between the mean pairwise distance during AIM and
CONV (Wilcoxon matched-pairs test; BC AIM versus BC CONV, P 0.001; OW AIM versus
OW CONV, P 0.01). This analysis suggested that genetic diversity was decreasing over
time and, in addition, converging to a genotype that was more closely related to the
B95.8 reference genome.
Whole EBV genomes become more similar to the B95.8 reference strain over
time. Several independent observations suggested that EBV genomes sequenced from
circulating B cells and oral wash samples tend to become more similar to the reference
strain, B95.8, over time. For example, phylogenetic analysis (Fig. 2) displayed clear
clustering of B cell CONV sequences (Fig. 2, marked by black dots) with the B95.8
reference genome, regardless of the branching pattern from related sequences from
the same patient (e.g., E1578 sequences). To get a clearer sense of the relationship
between length of infection and level of convergence with the reference strain, the
genetic distance of each full-length patient consensus genome from the reference
genome of B95.8 was determined and plotted as a function of time (number of days
between AIM and CONV visits [Table 1]). As Fig. 5A indicates, several EBV genomes
sequenced from patient oral washes during CONV were more similar (shorter genetic
distance) to the B95.8 reference sequence than those sequenced from the same
FIG 3 The majority of variations in EBV ORFs are synonymous amino acid changes to viral genes required for latent infection. (A) Sites of synonymous and
nonsynonymous nucleotide variations present in patient samples organized by gene. The height of the bar represents nucleotide changes per 1,000 base pairs.
(B) Both synonymous and nonsynonymous sites are increased in the latent gene subset compared to these sites in the early and late gene groups. (C) Ratio
of nonsynonymous to synonymous nucleotide changes (dN/dS) suggests some positive selective pressure on genes in the latent subset. The bars represent the
mean accumulated variation determined in the 40 sequenced patient samples. Genes were annotated based on B95.8 (NCBI accession number NC_007605.1)
and allotted to latent, late, and early groups based on a previously established convention. (Mann-Whitney test; *, P  0.0001).
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patients during AIM. In a similar analysis of the full-length EBV genomes sequenced
from B cells, 7 of the 10 matched sequences showed convergence toward the reference
strain of B95.8 during CONV (Fig. 5B). A Spearman rank-order correlation test indicated
a negative correlation (r0.5589; P 0.0264) between genetic distance to B95.8 and
length of infection, which is to say that patient samples sequenced after a greater
length of infection were more likely to be closer in sequence identity to B95.8. This
convergence phenomenon was speciﬁc for the B95.8 genome and was not observed for
any other type I or type II EBV reference genome (Fig. 5C).
EBV genomic diversity varies by gene, compartment, and over time. We then
evaluated diversity within individual EBV genes at the nucleotide level. Pairwise genetic
FIG 4 Diversity in EBV genomes is detectable intrahost and varies by compartment and time. (A)
Intrahost pairwise diversity for all four sequences generated from each patient is plotted as a box-and-
whisker plot showing the median (between light and dark gray), upper and lower bins, and outliers.
Whiskers extend to 1.5 times the interquartile range. Each of the four sequences results in six paired-
distance values. (B) Pairwise distances for sequences from each compartment and time point grouped
together and plotted as described for panel A, with 10 patient samples per compartment, or a total of
45 paired values. (C) Pairwise distances for each sequence in panel B from the reference genome B95.8
(10 values). Stars indicate signiﬁcant differences in distances from AIM to CONV (Wilcoxon test; P 0.01).
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distances for each time point and compartment were calculated for six glycoproteins
(Fig. 6) and six latency genes (Fig. 7). We examined within-cohort distance for each
gene (Fig. 6 and 7, top panels) and distance from B95.8 (Fig. 6 and 7, bottom panels).
Overall, glycoproteins were much less diverse than latent genes (note scale on the y
axis). However, despite their low diversity, signiﬁcant differences were observed in the
intrahost distances of gp350, gp42, gH, gB, and gL between time point and compart-
ments (Fig. 6, top panel). For example, gp350 demonstrated signiﬁcantly reduced
diversity of B cell- and oral wash-derived EBV sequences from AIM to CONV although
a much greater reduction was observed in the BC population. A similar pattern of
reduction in diversity was also observed for gB and gH sequence populations. In
contrast, sequence diversity in gp42, gp85, and gL increased signiﬁcantly in BC-derived
virus sequenced during CONV (Wilcoxon matched-pairs test, P  0.01). When pairwise
distance was compared to that of the reference genome (Fig. 6, lower panel), gp350 BC
sequence populations showed signiﬁcantly reduced diversity from AIM to CONV,
indicating a convergence toward the reference genome (BC AIM versus BC CONV
gp350, P  0.05).
Similarly, each of the six latency genes demonstrated different patterns of variation,
indicating that the genes were not strictly linked. For example, EBNA1 mean distances
were signiﬁcantly lower during AIM than during CONV, in both BC and OW (Wilcoxon
test; BC AIM versus BC CONV, P  0.0013; OW AIM versus OW CONV, P  0.0012); this
trend was reversed for EBNA2, EBNA3C, and LMP1 (Fig. 7, top panel) where there was
signiﬁcantly lower diversity during CONV than during AIM (Wilcoxon test; P  0.05 for
all pairings). In EBNA3B the mean diversity for BC-associated viral sequences increased
signiﬁcantly from AIM to CONV in B cells although a signiﬁcant reduction was noted in
OW-associated sequences (Wilcoxon test; P 0.05). LMP2 distances remained about the
same for collection time and compartment.
TABLE 1 Participant characteristics
Participant no. Gender Age (yr)
Time of
visit
Serologya Viral load by sample type
IgM VCA IgG VCA EBV nuclear Ag
B cell (copies/
106 B cells)
Oral wash
(copies/ng of DNA)
E1492 M 20.4 AIM Pos Neg Neg 55,094 234.3
21.0 CONV 1,983 0.7
E1503 M 19.3 AIM Pos Neg Neg 111,092 2.9
19.7 CONV 271 2.9
E1536 F 19.3 AIM Pos Neg Neg 28,247 23.7
19.8 CONV 4,581 0.8
E1548 F 18.7 AIM Pos Neg Neg 23,263 0.4
19.2 CONV 1,081 0.2
E1563 M 21.8 AIM Pos Neg Neg 2,391 3.1
22.3 CONV 388 1.0
E1577 M 20.3 AIM Pos Pos Neg 64,825 1.9
21.1 CONV 375 0.6
E1578 F 20.0 AIM Pos Pos Neg 4,523 10.8
20.8 CONV 3,283 0.1
E1583 F 18.9 AIM Pos Pos Neg 410,435 13.1
19.6 CONV 839 0.5
E1587 F 19.9 AIM Pos Neg Neg 54,060 1.8
20.6 CONV 596 0.1
E1590 M 18.4 AIM Pos Pos Neg 8,127 1.4
19.0 CONV 271 0.3
aVCA, viral capsid antigen; Ag, antigen.
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The pairwise distance for each gene to annotated ORF of the full-length B95.8
reference genome was also calculated. In ﬁve of the six genes studied (EBNA1, EBNA3B,
EBNA3C, LMP1, and LMP2), the BC CONV sequences were more similar to those of the
reference genome than BC AIM sequences; measurements of mean genetic distance
indicated signiﬁcant differences between the AIM and CONV time points (Fig. 7, lower
FIG 5 Full-length EBV genomes sequenced from circulating B cells, but not oral wash samples, of patients during
primary EBV infection converge toward a common B95.8 reference-like genome over time. EBV genomes were
sequenced from either oral wash (A) or B cell compartment (B) samples during AIM and CONV, and their genetic
distances from the prototypical reference genome B95.8 were determined. Repeat regions and incompletely
sequenced stretches greater than 10 nucleotides were masked in all samples as well as in the reference genome
prior to alignment and subsequent phylogenetic tree formation. (C) The observed convergence toward a common
reference genome appears to speciﬁcally favor a B95.8-like sequence rather than alternate type I EBV strains such
as Akata, Mutu, GD, etc., or type II strains.
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panel) (Wilcoxon ranked-pairs test, signiﬁcance values from P  0.05 to P  0.01). In
contrast to the observations in B cell-associated virus, only one gene, LMP2, was found
to converge toward B95.8 in virus sequenced from OW during the same time frame
(Wilcoxon ranked-pairs test; LMP2 OW AIM versus OW CONV, P  0.01).
DISCUSSION
Next-generation sequencing, coupled with methods used to enrich viral genomes
from contaminating human genomes, has proven to be a powerful tool for sequencing
and characterization of full-length viral genomes, including EBV. In the past 5 years
alone, the number of publicly available EBV genome sequences has increased from
under 10 to greater than 100 (26, 29). While these studies have provided novel
sequence data that increase our understanding of EBV biology, the overwhelming
majority of genome sequences originated in either diseased tissue or from immortal-
ized cell lines. Either of these two conditions may have imposed selective pressures on
FIG 6 Overall genetic diversity in EBV glycoproteins is low but varies between time and compartment. The top
panel shows the box-and-whisker plot of the genetic distances between all sequences in our cohort for each
indicated gene (total of 45 values per time point/compartment). The bottom panel shows the box-and-whisker plot
genetic distances from each sequence to the reference genome B95.8 for the same gene (10 values). Several data
points for each gene overlapped and caused the apparent reduction in sample number. For each gene, the plots
are ordered BC AIM (blue), OW AIM (red), BC CONV (orange), and OW CONV (green). Stars indicate signiﬁcant
changes from AIM to CONV for BC and OW sequence populations (Wilcoxon matched-pairs signed-rank test; P 
0.05).
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the viral genome, and the extent to which these sequences represent circulating EBV
strains has not been clear. Although our cohort is limited in size, this study is the ﬁrst
to directly sequence whole EBV genomes from otherwise healthy patients over the
course of primary infection. These sequences originated from circulating B cells and oral
wash samples and were collected during both the acute phase of infection and
convalescence.
Phylogenetic analyses of our sequences suggested that all 10 patients were infected
with a type I strain of EBV, which was expected, given the geographic location of the
study. As noted, almost all of the sequences aligned with the B95.8 and Mutu reference
genomes, two type I EBV strains isolated from North America and Kenya, respectively.
Sequences collected from our patient cohort clustered away from type I Asian strains
(e.g., Akata, GD1, and GD2). While this could possibly be explained by the choice of
using two type I genomes (B95.8 and Akata) as templates for our baits, similar probe
sets have been used by other groups to successfully capture both type I and type II EBV
genomes (17, 18), suggesting that our sequences accurately represent the strains
circulating in the sampled population.
The levels of individual gene and protein variation detected in the viral genomes of
our patient cohort are consistent with those previously published (18). High levels of
FIG 7 Latent genes from circulating EBV genomes are diverse during AIM but become less diverse over time and
more similar to B95.8 latent genes. The top panel shows the box-and-whisker plot of the genetic distances between
all sequences in our cohort for each indicated latent gene (total of 45 values per time point/compartment). The
bottom panel shows the box-and-whisker plot of genetic distances from each sequence to the reference genome,
B95.8, for the same gene (10 values). For each gene, the plots are ordered BC AIM (blue), OW AIM (red), BC CONV
(orange), and OW CONV (green). Stars indicate signiﬁcant changes from AIM to CONV for BC and OW sequence
populations (Wilcoxon matched-pairs signed-rank test; P  0.05).
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variability (both synonymous and nonsynonymous) were detected in latent genes
(EBNA1, EBNA2, EBNA3C, and LMP1), particularly compared to the variation observed in
early and late lytic genes. We did not detect higher levels of nonsynonymous variation
reported in a recent analysis of 83 full-length genomes primarily from tumor tissues and
cell lines. This may reﬂect different selective pressures operating across tissue type and
disease process; variability may also be higher in EBV genomes sequenced from
different cancerous tissues where DNA proofreading and repair may be impaired. In
addition, the 40 genomes reported here originated from only 10 patients, making it
much more likely that they would share the same variants. The technique employed in
our study, enriching for viral genomes from infected human cells with low viral genome
copy number, could be effectively utilized to directly compare circulating viral genomes
to tissue-associated viral genomes in the same patient to better understand these
apparent discrepancies.
Similar to our previously reported observations in a comparable cohort, we found
signiﬁcant intrahost EBV genomic diversity between samples taken from B cells and
those from oral washes over time (15). We previously reported an increase in LMP1
diversity from AIM to CONV in OW-derived virus; in this study, diversity at both the
full-length genome level and in LMP1 were determined to decline from AIM to CONV
in both BC- and OW-derived virus (Fig. 4 and 7). This discrepancy can be attributed to
the nature of the comparison in our prior work as well as to the increased sensitivity of
the current library preparation and sequencing. Our previous study focused solely on
LMP1 sequences directly ampliﬁed from patients with acute or chronic infection;
because we were not able to study all patients at both time points, we were unable to
directly compare diversity at the two time points for each compartment, and compar-
isons were made between group values (15). In addition, in the patient sets that were
complete (contained all four samples), we failed to detect any LMP1 variants in three
of the ﬁve sets, which thus disproportionately skewed the effect of variants in the
convalescent oral wash samples. The increased sensitivity of our new enrichment and
sequencing approach allowed us to accurately detect and determine LMP1 variants in
all patient samples.
This ﬁnding highlights one of the particular strengths of our current study with this
cohort, i.e., the ability to quantify changes in viral diversity over time within the same
patient, beginning with primary infection. The few full-length EBV genomes that have
been sequenced directly from patients have described samples from a single collection
time point and from only one sample type. While these data reﬂect the overall level of
EBV variation potential present in circulating virus, they do not reﬂect the identity of the
infecting virus or the rate of viral evolution following infection. Our data suggest that
all 10 patients may have been infected with different strains of type I EBV. The diversity
detected in both the B cell- and oral wash-associated virus during AIM could be the
result of initial infection with a diverse pool of EBV, or the diversity could have arisen
over the course of several rounds of early virus replication in the newly infected host
(43, 44). Regardless, changes in EBV genomic variation within each patient (as measured
by genetic distance) indicated continuing evolution of the viral genome in both the
peripheral blood B cells and the oral compartment (Fig. 4).
A signiﬁcant reduction in overall EBV genomic diversity was detected in the se-
quences of B cell-associated virus from AIM to CONV (Fig. 4B). Changes in latent genes
accounted for most of the loss of viral genomic diversity in B cell EBV sequences over
time (Fig. 7, top panel). Three of six latent genes (EBNA2, EBNA3C, and LMP1) demon-
strated signiﬁcantly lower mean genetic distances in B cells during CONV than during
AIM, a trend that was also observed in OW samples. Signiﬁcantly lower mean genetic
distances were also detected in CONV blood gp350, gH, and gB sequences and oral
wash gp350, gH, and gB sequences (Fig. 6, top panel). Additional studies will be helpful
in discerning whether this indicates separate and discrete selection pressures operant
on these genes. Certainly, envelope glycoprotein variation is subject to selection
pressure by antibody activity (16), whereas latent gene variability may be driven more
by CD8 T cell selective pressures.
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Perhaps the most striking ﬁnding was the apparent convergence of B cell-associated
EBV genomes toward a B95.8-like reference genotype over time (Fig. 5B); this was
apparent at both the whole-genome level as well at the level of selected, individual
genes (Fig. 6 and 7, bottom panels). With our access to longitudinal samples, we
showed a strong negative correlation between length of infection and genetic distance
from B95.8 (Spearman correlation; r  0.5589; P  0.0264); that is, the longer an
individual was infected, the more likely the B cell EBV sequence was to resemble B95.8.
Though B95.8 was isolated from a patient during AIM, the suspected origin of the virus
was latently infected B cells delivered via transfusion; the reference genome was
subsequently selected by its ability to transform marmoset B cells, perhaps explaining
how this strain is representative of longer-term infection seen in our samples (42). We
also demonstrated that the convergence toward a reference genome is speciﬁc for
B95.8, the prototypic type I virus geographically linked to North America, and not
another type I reference genome (e.g., Akata or Mutu) (Fig. 5C). This observation was
even more pronounced at the protein level for gp350 and LMP1 (data not shown). We
anticipate that a similar cohort assembled from a different geographic locale might
demonstrate the same trend toward the nearest reference strain for that region.
It is unlikely that utilization of a B95.8 BAC for the generation of our hybridization
probes reduced the diversity of our libraries, skewing our results toward the reference
genome. Prior studies utilizing hybridization to enrich EBV genomes have used probes
designed from the B95.8 reference genome and were able to assemble type I and type
II EBV genomes (17, 18). Probes were a 50:50 mix of B95.8 and Akata BAC genomes (see
Materials and Methods), yet we observed convergence toward B95.8 only, and not
Akata or a B95.8-Akata hybrid (Fig. 5C). Finally, identity with B95.8 was independent of
total sequencing reads or depth and thus independent of viral load (Table 1, viral load;
see also read information in Table S1 in the supplemental material). In fact, low depth
would be predicted to result in a greater amount of variation as there are insufﬁcient
reads to determine true SNPs from sequencing errors; in contrast, we ﬁnd that regard-
less of overall sequencing depth (particularly in CONV B cells where copy numbers are
expected to be lower) similarity to B95.8 is striking. Similarly, even when samples had
comparable viral loads (e.g., E1578 BC AIM and BC CONV) (Table 1), detectable
differences in the EBV genomes were observed.
Convergence of viral genomes toward a consensus sequence over time following
infection has previously been described in RNA viruses. A recent study reported
duplication in a region of the respiratory syncytial virus (RSV) G glycoprotein; this
duplication was noted to occur independently in two separate and otherwise unrelated
strains, likely as an adaptation for immune evasion (45). Interestingly, the hepatitis C
virus (HCV) G proteins from infected patients sequenced 20 years after a common-
source outbreak indicated convergent evolution in HCV in the absence of speciﬁc HLA
alleles (46). The latter data suggest that the consensus sequence provides a selective
advantage, perhaps favoring persistence within a reservoir or for transmission to a new
host. Indeed, convergence of HIV env sequences toward an ancestral version better
adapted for transmission has been reported in HIV-positive patients (47, 48).
We note the obvious differences in convergence levels across the genes discussed
here; not all genes appear to converge, and those that do likely converge at different
rates. Also, some of the most signiﬁcant convergence detected is within the most
variable genes. Both of these observations can be explained by the complex replication
cycle and gene expression pattern of EBV. For example, although genes such as EBNA1
and LMP1 are indeed the most variable, they are also the most expressed during the
establishment of latent infection, exposing them to both functional and immunological
pressure, particularly cytotoxic T lymphocyte (CTL) recognition. However, all study
participants were HLA-A2 positive, and analysis of common HLA-A2 epitopes did not
reveal evolution of any potential CTL escape mutations in either BC or OW samples
from AIM to CONV (Table S3 and data not shown) (49).
Interestingly, we did not ﬁnd any relationship between peripheral blood viral load
and intrahost diversity; EBV copy number did not correlate with total variation in B
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cell-derived virus at either time point (data not shown). As noted above, this was not
likely due to any artifactual effect of sequencing depth as samples with similar viral
loads generated measurably different genomic sequences. Likewise, the reciprocal
interaction was also observed; despite a greater than 400-fold difference in BC viral
loads from AIM to CONV (Table 1), sequences obtained from patient E1503 demon-
strated remarkable conservation, clustering together with matched OW sequences from
both time points to form a distinctive group (Fig. 2). Furthermore, no correlation was
detected between depth of coverage and detection of viral variants; Spearman analysis
of FPKM scores versus variation at the individual ORF failed to indicate any correlation
(data not shown). Last, no correlation was detected between viral load values and
genome diversity (data not shown), suggesting that the reduction in viral diversity
measured during CONV was not due to reduction in genome sample size. This evidence
indicates that reduced viral copy number during convalescence, particularly in B cells,
did not negatively impact the ﬁndings in this study.
The current model posits transfer of EBV in saliva from an infected donor and
subsequent infection of naive B cells in the new host (50). These naive cells undergo a
germinal cell-like reaction and transition into memory B cells persistently infected with
a latent EBV genome expressing a severely limited number of gene products (51–53).
Activation of these memory B cells results in lytic replication of EBV and produces virus
that greatly favors infection of epithelial cells, further amplifying the virus (54). During
early infection, in the absence of an adaptive immune response, this cycle can result in
greater than 50% of circulating memory B cells being positive for EBV (55). Alternatively, it
has also been suggested that incoming virus released from donor B cells is ﬁrst ampliﬁed
by direct infection of epithelial tissue to generate a lymphotropic virus prior to naive B cell
infection (56, 57). Both of these paths of infection may affect the levels of viral diversity
detected in either compartment during AIM as any replication event has the potential to
increase genomic variation (13). Our compartment sequencing data and those from similar
studies moving forward may provide further information on which proposed infection
mechanism may be operant.
Although the data described here provide valuable information regarding overall
viral diversity as well as viral genome evolution during EBV infection, additional
questions will need to be addressed. Our data indicate that certain EBV glycoprotein
and latent genes required for the establishment and persistence of B cell infection,
despite being some of the most variable, demonstrated the greatest degree of con-
vergence over time. This suggests that conservation of genomic segments is important
for persistent infection. However, additional analyses at the individual gene level are
required to determine what speciﬁc functions may be selected for over the course of
persistent infection. This quasi-species-level analysis is important to answering these
questions and to better appreciate the various push-pull mechanics of immune evasion
versus gene functionality. Additionally, the origin of the B95.8-like genome sequenced
in our patients will need to be resolved. Does it arise through spontaneous mutation of
diverse transmitted EBV genomes, or is it present during transmission and out-
competes other EBV variants? Answering these questions will require additional studies
that leverage new technologies, including single-cell sequencing to track individual,
complete viral genomes through time.
MATERIALS AND METHODS
Study cohort. Peripheral blood mononuclear cell (PBMC) and saliva samples were obtained from 10
young adults (5 male and 5 female) presenting with symptoms compatible with AIM; AIM diagnosis was
conﬁrmed by a positive monospot assay (University of Massachusetts Amherst Health Services). Primary
infection was conﬁrmed by the detection of serum IgM speciﬁc for the EBV viral capsid antigen (Table
1) (58). Additional blood and oral wash samples were collected from the same 10 patients at least 5
months postinfection (CONV).
Quantiﬁcation of viral genomes in peripheral blood. EBV genomes present in the peripheral
blood and saliva were quantiﬁed using a previously described quantitative PCR (qPCR)-based viral load
assay (16). Brieﬂy, circulating B cells were isolated from PBMCs using a RosetteSep human B cell kit
(StemCell Technologies), and total DNA was extracted using a Qiagen DNeasy blood and tissue kit
(Qiagen). DNA from oral wash samples was isolated using a High Pure Viral Nucleic Acid kit (Roche
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Diagnostics) following preclearing of samples by low-speed centrifugation. The EBV copy number per human
genome was determined using duplexed qPCRs to simultaneously quantify the number of EBV BALF5 copies
(forward primer, 5=-CGGAAGCCCTCTGGACTTC-3=; reverse primer, 5=-CCCTGTTTATCCGATGAATG-3=; and
probe 5=-FAM-TGTACACGCACGAGAAATGCGCCT-BHQ-1-3=, where FAM is 6-carboxyﬂuorescein and BHQ is
Black Hole quencher); human genome copies were determined by quantifying the copy number of the
CCR5 gene (forward primer, 5=-GCTGTGTTTGCGTCTCTCCCAGGA-3=; reverse primer, 5=-CTCACAGCCCTG
TGCCTCTTCTTC-3=; and probe 5=-Cy5-AGCAGCGGCAGGACCAGCCCCAAG-BHQ-1-3=). DNA extracted from
the Namalwa cell line, containing two integrated copies of the EBV genome, was used to establish
standards and controls (59).
EBV bait preparation. Two sets of EBV whole-genome baits (WGB) from BACs containing the
full-length EBV genomes of either B95.8 or Akata were prepared as described previously (31). Brieﬂy,
3 g of DNA was sheared to an average size of 250 bp using a Covaris S220 instrument. End repair,
addition of a 3= A, adapter ligation, and reaction cleanup followed the Illumina’s genomic DNA sample
preparation protocol except that the adapter consisted of oligonucleotides 5=-TGTAACATCACAGCATCA
CCGCCATCAGTCxT-3= (where x refers to an exonuclease I-resistant phosphorothioate linkage) and
5=-[PHOS]GACTGATGGCGCACTACGACACTACAATGT-3=. The T7 RNA polymerase promoter sequence was
added by PCR using the forward primer 5=-GGATTCTAATACGACTCACTATAGGCGCTCAGCGGCCGCAGCA
TCACCGCCATCAGT-3=, and the puriﬁed PCR product was used as the template to generate biotinylated
RNA baits using a MEGAshortscript T7 kit (Thermo Fisher). WGB from EBV B95.8 and Akata genomes were
mixed at a 1:1 ratio and used for hybrid selection.
Patient sample pond library prep. Three micrograms of DNA extracted from either patient oral
washes or peripheral blood B cells was sheared using a Covaris S220 Sonicator (Covaris) and concen-
trated using a MinElute kit (Qiagen). Sheared DNA was enzymatically blunted and end repaired with T4
DNA polymerase and polynucleotide kinase (PNK), and 3= A tails were added using Klenow DNA
polymerase prior to ligation of sequencing adapters. Forty-one unique nucleotide-barcoded sequencing
adapters were used for each of the patient samples, as well as the resequenced EBV Akata-containing
BAC. Following ligation, libraries were ampliﬁed by PCR for either 8, 10, or 12 cycles using the forward
primer 5=-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGA-3= and reverse primer 5=-CAAGC
AGAAGACGGCATACGAGAT-3= and 2 Phusion PCR Mastermix (New England BioLabs). The ﬁnal ampli-
ﬁed patient pond libraries were puriﬁed using AMPure XP beads, and DNA concentration was deter-
mined using a Qubit 2.0 Fluorometer (Life Technologies).
Enrichment of EBV genomes from patient samples. We applied hybrid selection with WGB to
enrich EBV genomes in patient pond libraries prepared from oral washes or peripheral blood B cells.
Forty-one unique barcoded sequencing adapters were used for each of the patient samples as well as
for the resequenced EBV Akata-containing BAC control. For enrichment, we hybridized DNA of the pond
library (1 to 2 g) with EBV B95.8-Akata WGB (0.5 g) as described previously (30, 31).
Sequencing. Each sample was sequenced by Beckman Coulter Genomics; all four patient libraries
constructed from AIM and CONV B cell fraction (BC)- and oral wash (OW)-extracted viral genomes were
run on the same lane of an Illumina HiSeq 2500, across two ﬂow cells, as 2- by 125-bp runs. Sequences
were parsed according to barcodes prior to sample analysis and genome assembly.
EBV sequence assembly methods. Fastq ﬁles were quality checked using FastQC (version 0.11.4)
and imported into Geneious Software (version 9.1.3). Any remaining adapter sequences were trimmed
using the BBduk plug-in in Geneious. Guided by FastQC statistics, reads for each ﬁle were further
trimmed to a level of 99 to 100% inferred base call accuracy. Paired reads were mapped to the NCBI EBV
reference genome (NC_007605.1) using the Geneious Read Mapper set to a medium to high sensitivity.
A consensus sequence was called for each set of contigs using the highest quality threshold based on
the chromatograms, with an N called for any position where coverage was less than ﬁve contigs. A
summary of the paired reads, assembled reads, percent mapped reads, and reference coverage is
provided (see Table S1 in the supplemental material). Mean coverage denotes coverage across the entire
length of the EBV genome, including regions of high-GC content and repetitive DNA sequences; in
keeping with the current standards of analysis, these regions were masked for all alignments and
subsequent analyses. To ensure that coverage levels of all EBV ORFs were comparable, fragment per
kilobase million (FPKM) reads for each reported gene for each patient were calculated (Table S2).
Consensus sequences for each patient (BC AIM, BC CONV, OW AIM, and OW CONV) were aligned to each
other using MAFFT (http://mafft.cbrc.jp/alignment/server/) and manually proofed against their assem-
blies to determine if additional bases could be called.
All subsequent analyses utilized consensus sequences generated from Illumina assemblies. MAFFT
(version 7) was used to align the 40 subjects’ consensus sequences to the NCBI reference genome. The
alignment was optimized by hand to correct for poorly sequenced and/or repeat regions. Repeat regions
with assembly errors were masked for subsequent distance and phylogenetic calculations. A maximum-
likelihood phylogenetic tree was generated using PhyML (http://www.atgc-montpellier.fr/phyml/) and
the Akaike information criterion (AIC) (60). The alignment was annotated according to the reference
genome in Geneious (Fig. 1). Coding regions were extracted from the alignment and checked for proper
translation prior to distance-based calculations. Within each coding region, overall nonsynonymous (dN)
and synonymous (dS) genetic distances were calculated using SNAP (www.lanl.gov). Estimates of
genomic diversity within and between sequence populations were calculated in MEGA using the
Tamura-Nei (TN93) molecular model (identiﬁed as the best-ﬁtting model using the hierarchical test based
on the Bayesian information criterion), and standard errors were calculated using a bootstrap procedure
(1,000 replicates) (61, 62). Pairwise distances were calculated for each subject’s consensus sequences (4
sequences each; 6 pairwise comparisons), for each compartment during either AIM or CONV (10 patient
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sequences; 45 pairwise comparisons), and relative to the NCBI reference genome (the genetic distance
of each sequence to the reference genome; 10 pairwise comparisons) (Fig. 4). Similarly, pairwise
distances were calculated for speciﬁc genes (Fig. 6).
Statistical analysis. Statistical analyses were performed using GraphPad Prism, version 7.03, for
Windows (GraphPad Software, San Diego, CA). Correlations for non-normally distributed data were
calculated using Spearman’s rank correlation coefﬁcient (rho). Comparison of pairwise distance mea-
surements for AIM patients during AIM and CONV were calculated using Wilcoxon matched-pairs
signed-rank test; comparisons between EBV gene groups were calculated using a Mann-Whitney test. All
statistical tests were two-sided, and a P value of 0.05 was considered statistically signiﬁcant.
Ethics statement. All study participants provided written informed consent, and the University of
Massachusetts Medical School IRB approved these studies.
Accession number(s). Consensus sequence data from this study have been deposited in the NCBI
database under accession numbers MF547453 to MF547492 (Table 2). NCBI accession numbers of
previously determined full-length EBV sequences used in analysis are as follows: Akata, KC207813; B95.8,
NC_007605.1; C666-1, LN827525; GD1, AY961628; GD2, HQ020558; healthy donor saliva, LN824142;
Mutu, KC207814; M81, KF373730; AG876, NC_009334; Jijoye, LN827800; and Wewak, LN827544.
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